Results 41 to 50 of about 38,268 (270)

Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives. [PDF]

Oncotarget, 2019
Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current ...
Lehman JM, aMassion PP.
europepmc   +4 more sources

Growing vascular endothelial cells express somatostatin subtype 2 receptors [PDF]

British Journal of Cancer, 2001
We hypothesized that non-proliferating (quiescent) human vascular endothelial cells would not express somatostatin receptor subtype 2 (sst 2) and that this receptor would be expressed when the endothelial cells begin to grow. To test this hypothesis, placental veins were harvested from 6 human placentas and 2 mm vein disks were cultured in 0.3% fibrin ...
Watson, J C, Balster, D A, Gebhardt, B M, O'Dorisio, T M, O'Dorisio, M S, Espenan, G D, Drouant, G J, Woltering, E A   +7 more
openaire   +2 more sources

Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

Clinics
OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades.
Maria de Fátima Borges, Beatriz Hallal Jorge Lara, Janaíne Machado Tomé, Leopoldo Prezia de Araújo, Flávio Cesar Lucas Bugiga, Júlio Cláudio Sousa, Jacqueline Mendes Fonseca Soares, Roberto Alexandre Dezena, Beatriz Pires Ferreira   +8 more
doaj   +1 more source

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

EJNMMI Research, 2020
Background Somatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors.
Rosalba Mansi, Karim Abid, Guillaume P. Nicolas, Luigi Del Pozzo, Eric Grouzmann, Melpomeni Fani   +5 more
doaj   +1 more source

Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine

Nature Communications, 2023
Somatostatin receptor 2 (SSTR2) represents a therapeutic target of neuroendocrine tumors. Here, authors report two structures of SSTR2 bound to peptide octreotide and small molecule paltusotine, revealing the basis subtype selectivity and signal bias ...
Jie Zhao, Hong Fu, Jingjing Yu, Weiqi Hong, Xiaowen Tian, Jieyu Qi, Suyue Sun, Chang Zhao, Chao Wu, Zheng Xu, Lin Cheng, Renjie Chai, Wei Yan, Xiawei Wei, Zhenhua Shao   +14 more
doaj   +1 more source

Constitutive Somatostatin Receptor Subtype 2 Activity Attenuates GH Synthesis [PDF]

Endocrinology, 2013
AbstractSomatostatin signals predominantly through somatostatin receptor (SSTR) subtype 2 to attenuate GH release. However, the independent role of the receptor in regulating GH synthesis is unclear. Because we had previously demonstrated constitutive SSTR2 activity in mouse corticotrophs, we now analyzed GH regulation in rat pituitary somatotroph (GC)
Anat, Ben-Shlomo, Oxana, Pichurin, Ramtin, Khalafi, Cuiqi, Zhou, Vera, Chesnokova, Song-Guang, Ren, Ning-Ai, Liu, Shlomo, Melmed   +7 more
openaire   +2 more sources

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

International Journal of Endocrinology, 2017
The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA).
Wenjuan Liu, Lina Xie, Min He, Ming Shen, Jingjing Zhu, Yeping Yang, Meng Wang, Ji Hu, Hongying Ye, Yiming Li, Yao Zhao, Zhaoyun Zhang   +11 more
doaj   +1 more source

Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review

Current Issues in Molecular Biology, 2022
We compared head-to-head the most used radiolabeled peptides for single photon computed emission tomography (SPECT) and positron emission tomography (PET) imaging of neuroendocrine tumors (NETs). A comprehensive literature search was performed in PubMed,
Giulia Poletto, Diego Cecchin, Stefania Sperti, Luca Filippi, Nicola Realdon, Laura Evangelista   +5 more
doaj   +1 more source

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms

Pharmaceuticals, 2017
: Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics ...
Melpomeni Fani, Petra Kolenc Peitl, Irina Velikyan   +2 more
doaj   +1 more source

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Frontiers in Endocrinology, 2022
Somatostatin exhibits an inhibitory effect on pituitary hormone secretion, including inhibition of growth hormone and adrenocorticotropic hormone (ACTH), and it can have antisecretory and antitumor effects on neuroendocrine tumors (NETs) that express ...
Rosario Pivonello, Pamela N. Munster, Massimo Terzolo, Rosario Ferrigno, Chiara Simeoli, Soraya Puglisi, Utsav Bali, Andreas G. Moraitis   +7 more
doaj   +1 more source